Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib.
Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib.
Cardiovasc Toxicol. 2020 Mar 02;:
Authors: Hasinoff BB, Patel D
Abstract
The anticancer drug dasatinib (Sprycel) is a BCR-ABL1-targeted tyrosine kinase inhibitor used in treating chronic myelogenous leukemia that has been shown in clinical trials to display cardiovascular toxicities. While dasatinib potently inhibits BCR-ABL1, it is not a highly selective kinase inhibitor and may have off-target effects. A neonatal rat cardiac myocyte model was used to investigate potential mechanisms by which dasatinib damaged myocytes. The anthracycline cardioprotective drug dexrazoxane was shown to be ineffective in preventing dasatinib-induced myocyte damage. Dasatinib treatment increased doxorubicin accumulation in myocytes and doxorubicin-induced myocyte damage, likely through its ability to bind to one or more ABC-type efflux transporters. Dasatinib induced myocyte damage either after a brief treatment that mimicked the clinical situation, or more potently after continuous treatment. Dasatinib slightly induced apoptosis in myocytes as evidenced by increases in caspase-3/7 activity. Dasatinib treatment reduced pERK levels in myocytes most likely through inhibition of RAF, which dasatinib strongly inhibits. Thus, inhibition of the RAF/MEK/ERK pro-survival pathway in the heart may be, in part, a mechanism by which dasatinib induces cardiovascular toxicity.
PMID: 32124237 [Pu...
Source: Cardiovascular Toxicology - Category: Cardiology Authors: Hasinoff BB, Patel D Tags: Cardiovasc Toxicol Source Type: research
More News: Cardiology | Cardiovascular | Chronic Leukemia | Chronic Myeloid Leukaemia | Clinical Trials | Heart | Leukemia | Perinatology & Neonatology | Toxicology